Equine sarcoids: Bovine Papillomavirus type 1 transformed fibroblasts are sensitive to cisplatin and UVB induced apoptosis and show aberrant expression of p53

详细信息    查看全文

• 作者：Margaret Finlay (1)
  ZhengQiang Yuan (2)
  Iain M Morgan (1)
  M Saveria Campo (1)
  Lubna Nasir (1)
  
• 刊名：Veterinary Research
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：43
• 期：1
• 全文大小：306KB
• 参考文献：1. Jackson C: The incidence and pathology of tumours of domesticated animals in South Africa. / Onderstepoort J Vet Sci Animal Indust 1936, 6:378鈥?85.
  2. Pascoe RR, Summers PM: Clinical survey of tumours and tumour-like lesions in horses in south east Queensland. / Equine Vet J 1981, 13:235鈥?39. CrossRef
  3. Ragland KWL, Keown GFH, Spencer GR: Equine Sarcoid. / Equine Vet J 1970, 2:2鈥?1. CrossRef
  4. Marti E, Lazary S, Antczak DF, Gerber H: Report of the first international workshop on equine sarcoid. / Equine Vet J 1993, 25:397鈥?07. CrossRef
  5. Goodrich L, Gerber H, Marti E, Antczack DF: Equine Sarcoids. / Vet Clin North Am Equine Prac 1998, 4:607鈥?23.
  6. Marais HJ, Nel P, Bertschinger HJ, Schoeman JP, Zimmerman D: Prevalence and body distribution of sarcoids in South African Cape mountain zebra (Equus zebra zebra). / J鈥塖 Afr Vet Assoc 2007, 78:145鈥?48.
  7. Knottenbelt DC: A suggested clinical classification for the equine sarcoid. / Clin Tech Eq Prac 2005, 4:278鈥?95. CrossRef
  8. Martens A, De Moor A, Demeulemeester J, Peelman L: Polymerase chain reaction analysis of the surgical margins of equine sarcoids for bovine papillomavirus DNA. / Vet Surg 2001, 30:460鈥?67. CrossRef
  9. Tarwid JN, Fretz PB, Clark EG: Equine sarcoids: a study with emphasis on pathological diagnosis. / Comp Cont Educ Pract 1985, 7:293鈥?00.
  10. Lane GJ: The treatment of equine sarcoids by cryosurgery. / Equine Vet J 1977, 9:127鈥?33. CrossRef
  11. Vingerhoets M, Diehl M, Gerber H, Stornetta D, Rausis C: The treatment of equine sarcoidosis by carbon dioxide laser. / Schweiz Arch Tierheilkd 1988, 130:113鈥?26. (in French)
  12. Knottenbelt DC, Kelly DF: The diagnosis and treatment of periorbital sarcoid in the horse: 445 cases from 1974 to 1999. / Vet Ophthalmol 2000, 3:169鈥?91. CrossRef
  13. Palmer SE: Treatment of common cutaneous tumors using the carbon dioxide laser. / Clin Tech equine Pract 2002, 1:43鈥?0. CrossRef
  14. Nogueira SA, Torres SM, Malone ED, Diaz SF, Jessen C, Gilbert S: Efficacy of imiquimod 5% cream in the treatment of equine sarcoids: a pilot study. / Vet Dermatol 2006, 17:259鈥?65. CrossRef
  15. Stadler S, Kainzbauer C, Haralambus R, Brehm W, Hainisch E, Brandt S: Successful treatment of equine sarcoids by topical aciclovir application. / Vet Rec 2011, 168:187. CrossRef
  16. Knottenbelt DC, Walker JA: Topical treatment of the equine sarcoid. / Equine Vet Ed 1994, 6:72鈥?5. CrossRef
  17. Knottenbelt DC, Edwards SER, Daniel EA: The diagnosis and treatment of equine sarcoids. / In Practice 1995, 17:123鈥?29. CrossRef
  18. Nasir L, Campo MS: Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids. / Vet Dermatol 2008, 19:243鈥?54. CrossRef
  19. Campo MS: Bovine papillomavirus: Old system, new lessons? In / Papillomavirus Research: From Natural History to Vaccines and Beyond. Edited by: Campo MS. Wymondham: England Caister Academic Press; 2006:373鈥?87.
  20. Ashrafi GH, Piuko K, Burden F, Yuan Z, Gault EA, M眉ller M, Trawford A, Reid SWJ, Nasir L, Campo MS: Vaccination of sarcoid-bearing donkeys with chimeric virus-like particles of bovine papillomavirus type 1. / J Gen Virol 2008, 89:148鈥?57. CrossRef
  21. Gobeil PA, Yuan Z, Gault EA, Morgan M, Campo MS, Nasir L: Small interfering RNA targeting bovine papillomavirus type 1 E2 induces apoptosis in equine sarcoid transformed fibroblasts. / Virus Res 2009, 145:162鈥?65. CrossRef
  22. Yuan Z, Gault EA, Campo MS, Nasir L: Different contribution of bovine papillomavirus type 1 oncoproteins to the transformation of equine fibroblasts. / J Gen Virol 2011, 92:773鈥?83. CrossRef
  23. Yuan ZQ, Gault EA, Gobeil P, Nixon C, Campo MS, Nasir L: Establishment and characterization of equine fibroblast cell lines transformed in vivo and in vitro by BPV-1: model systems for equine sarcoids. / Virology 2008, 373:352鈥?61. CrossRef
  24. Marchetti B, Gault EA, Cortese MS, Yuan Z, Ellis SA, Nasir L, Campo MS: Bovine papillomavirus type 1 oncoprotein E5 inhibits equine MHC class I and interacts with equine MHC I heavy chain. / J Gen Virol 2009, 90:2865鈥?870. CrossRef
  25. Yuan ZQ, Bennett L, Campo MS, Nasir L: Bovine papillomavirus type 1 E2 and E7 proteins down-regulate Toll Like Receptor 4 (TLR4) expression in equine fibroblasts. / Virus Res 2010, 149:124鈥?27. CrossRef
  26. Yuan Z, Gobeil PA, Campo MS, Nasir L: Equine sarcoid fibroblasts over-express matrix metalloproteinases and are invasive. / Virology 2010, 396:143鈥?51. CrossRef
  27. Yuan Z, Gault EA, Campo MS, Nasir L: Upregulation of equine matrix metalloproteinase 1 by bovine papillomavirus type 1 is through the transcription factor activator protein-1. / J Gen Virol 2011, 92:2608鈥?619. CrossRef
  28. Yuan Z, Gault EA, Campo MS, Nasir L: p38 mitogen-activated protein kinase is crucial for bovine papillomavirus type-1 transformation of equine fibroblasts. / J Gen Virol 2011, 92:1778鈥?786. CrossRef
  29. Th茅on AP, Pascoe JR, Carlson GP, Krag DN: Intratumoral chemotherapy with cisplatin in oily emulsion in horses. / J Am Vet Med Assoc 1993, 202:261鈥?67.
  30. Hewes CA, Sullins KE: Use of cisplatin-containing biodegradable beads for treatment of cutaneous neoplasia in equidae: 59 cases (2000鈥?004). / J Am Vet Med Assoc 2006, 229:1617鈥?622. CrossRef
  31. Tamzali Y, Borde L, Rols MP, Golzio M, Lyazrhi F, Teissie J: Successful treatment of equine sarcoids with cisplatin electrochemotherapy: a retrospective study of 48 cases. / Equine Vet J 2012, 44:214鈥?20. CrossRef
  32. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. / Oncogene 2003, 22:7265鈥?279. CrossRef
  33. Hern谩ndez Losa J, Parada Cobo C, Guinea Viniegra J, S谩nchez-Arevalo , Lobo VJ, Ram贸n Y, Cajal S, S谩nchez-Prieto R: Role of the p38 MAPK pathway in cisplatin-based therapy. / Oncogene 2003, 22:3998鈥?006. CrossRef
  34. Pfister H: Human papillomaviruses and skin cancer. / Semin Cancer Biol 1992, 3:263鈥?71.
  35. Jackson S, Storey A: E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. / Oncogene 2000, 19:592鈥?98. CrossRef
  36. McCauley CT, Hawkins JF, Adams SB, Fessler JF: Use of a carbon dioxide laser for surgical management of cutaneous masses in horses: 32 cases (1993鈥?000). / J Am Vet Med Assoc 2002, 220:1192鈥?197. CrossRef
  37. Carstanjen B, Jordan P, Lepage OM: Carbon dioxide laser as a surgical instrument for sarcoid therapy鈥揳 retrospective study on 60 cases. / Can Vet J 1997, 38:773鈥?76.
  38. Taylor ER, Boner W, Dornan ES, Corr M, Morgan IM: UVB irradiation reduces the half-life and transactivation potential of the human papillomavirus 16 E2 protein. / Oncogene 2003, 22:4469鈥?477. CrossRef
  39. Th茅on AP: Intralesional and topical chemotherapy and immunotherapy. / Vet Clin North Am Equine Pract 1998, 14:659鈥?71.
  40. Th茅on AP, Pascoe JR, Meagher DM: Perioperative intratumoral administration of cisplatin for treatment of cutaneous tumours in equidae. / J Am Vet Med Assoc 1994, 205:1170鈥?176.
  41. Ryan KM, Phillips AC, Vousden KH: Regulation and function of the p53 tumor suppressor protein. / Curr Opin Cell Biol 2001, 13:332鈥?37. CrossRef
  42. Rogel A, Popliker M, Webb CG, Oren M: p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. / Mol Cell Biol 1985, 5:2851鈥?855.
  43. Bucher K, Szalai G, Marti E, Griot-Wenk ME, Lazary S, Pauli U: Tumour suppressor gene p53 in the horse: identification, cloning, sequencing and a possible role in the pathogenesis of equine sarcoid. / Res Vet Sci 1996, 61:114鈥?19. CrossRef
  44. Nasir L, McFarlane ST, Reid SW: Mutational status of the tumour suppressor gene (p53) in donkey sarcoid tumours. / Vet J 1999, 157:99鈥?01. CrossRef
  45. Midgley CA, Lane DP: p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. / Oncogene 1997, 15:1179鈥?189. CrossRef
  46. Wang YC, Chen CY, Chen SK, Cherng SH, Ho WL, Lee H: High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. / Cancer Res 1998, 58:328鈥?33.
  47. Kubbutat MH, Jones SN, Vousden KH: Regulation of p53 stability by Mdm2. / Nature 1997, 387:299鈥?03. CrossRef
  48. Finch RA, Donoviel DB, Potter D, Shi M, Fan A, Freed DD, Wang CY, Zambrowicz BP, Ramirez-Solis R, Sands AT, Zhang N: mdmx is a negative regulator of p53 activity in vivo. / Cancer Res 2002, 62:3221鈥?225.
  49. Yamauchi M, Suzuki K, Kodama S, Watanabe M: Abnormal stability of wild-type p53 protein in a human lung carcinoma cell line. / Biochem Biophys Res Commun 2005, 330:483鈥?88. CrossRef
  50. Eichten A, Westfall M, Pietenpol JA, M眉nger K: Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein. / Virology 2002, 295:74鈥?5. CrossRef
  51. Moll UM, LaQuaglia M, Benard J, Riou G: Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. / Proc Natl Acad Sci U S A 1995, 92:4407鈥?411. CrossRef
  52. Moll UM, Riou G, Levine AJ: Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. / Proc Natl Acad Sci U S A 1992, 89:7262鈥?266. CrossRef
  53. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G: Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. / Mol Cell Biol 1996, 16:1126鈥?137.
  54. Wang X, Zalcenstein A, Oren M: Nitric oxide promotes p53 nuclear retention and sensitizes neuroblastoma cells to apoptosis by ionizing radiation. / Cell Death Differ 2003, 10:468鈥?76. CrossRef
  55. Oh W, Lee EW, Sung YH, Yang MR, Ghim J, Lee HW, Song J: jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2. / J Biol Chem 2006, 281:17457鈥?7465. CrossRef
  56. Nikolaev AY, Li M, Puskas N, Qin J, Gu W: Parc: a cytoplasmic anchor for p53. / Cell 2003, 12:29鈥?0. CrossRef
  57. Martens A, De Moor A, Demeulemeester J, Ducatelle R: Histopathological characteristics of five clinical types of equine sarcoid. / Res Vet Sci 2000, 69:295鈥?00. CrossRef
  58. Bogaert L, Van Poucke M, De Baere C, Dewulf J, Peelman L, Ducatelle R, Gasthuys F, Martens A: Bovine papillomavirus load and mRNA expression, cell proliferation and p53 expression in four clinical types of equine sarcoid. / J Gen Virol 2007, 88:2155鈥?161. CrossRef
  59. Johnston HM, Thompson H, Pirie HM: p53 immunohistochemistry in domestic animal tumours. / Eur J Vet Pathol 1996, 2:135鈥?40.
  60. Nixon C, Chambers G, Ellsmore V, Campo MS, Burr P, Argyle DJ, Reid SW, Nasir L: Expression of cell cycle associated proteins cyclin A, CDK-2, p27kip1 and p53 in equine sarcoids. / Cancer Lett 2005, 221:237鈥?45. CrossRef
  
• 作者单位：Margaret Finlay (1)
  ZhengQiang Yuan (2)
  Iain M Morgan (1)
  M Saveria Campo (1)
  Lubna Nasir (1)
  
  1. MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Inflammation and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Bearsden Road, Glasgow, Scotland, G61 1QH, United Kingdom
  2. Division of Life Sciences, University College, London, 5 University Street, London, WC1E 6JF, United Kingdom
  

文摘

Bovine papillomavirus type 1 infects not only cattle but also equids and is a causative factor in the pathogenesis of commonly occurring equine sarcoid tumours. Whilst treatment of sarcoids is notoriously difficult, cisplatin has been shown to be one of the most effective treatment strategies for sarcoids. In this study we show that in equine fibroblasts, BPV-1 sensitises cells to cisplatin-induced and UVB-induced apoptosis, a known cofactor for papillomavirus associated disease, however BPV-1 transformed fibroblasts show increased clonogenic survival, which may potentially limit the therapeutic effects of repeated cisplatin treatment. Furthermore we show that BPV-1 increases p53 expression in sarcoid cell lines and p53 expression can be either nuclear or cytoplasmic. The mechanism and clinical significance of increase/abnormal p53 expression remains to be established.